Difference between revisions of "Part:BBa K4160007"
Line 54: | Line 54: | ||
</body> | </body> | ||
</html> | </html> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
Latest revision as of 14:10, 11 October 2022
IL-10 (interleukin 10)
Interleukin 10 (IL-10) (Figure 1) is an anti-inflammatory cytokine, that has an essential role during infections. IL-10 inhibits the immune response during inflammation, to prevent damaging the host.1 IL-10 is not on the white list. However, the TU-Eindhoven 2022 team received permission from the Safety and Security Committee to implement the use of this part.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Usage and Biology
IL-10 originates from the Homo sapiens (human) and is the primary immune regulatory cytokine that has thorough anti-inflammatory functions while operating on many immune cells.2 IL-10 is primarily produced by monocytes and minorly by lymphocytes.3 It suppresses the expression of MHC class II proteins, Th1 cytokines, and costimulatory molecules on macrophages. Furthermore, IL-10 can enhance B-cell survival, proliferation, and production of antibodies.3 IL-10 is recognized to have potential therapeutic effects on inflammatory diseases, including autoimmune diseases.4
Role in autoimmune diseases
Since IL-10 lowers the inflammatory host response, it is co-responsible for preventing inflammation in autoimmune pathologies.5 Hence, IL-10 deficiency or dysregulation is acknowledged to cause several autoimmune diseases. Therefore, the powerful anti-inflammatory characteristics of IL-10 suggest the therapeutic potential of IL-10 administration in autoimmune diseases.5
GEMS system
TU-Eindhoven 2022 used this part as an output of the Generalized Extracellular Molecule Sensor (GEMS) system (BBa_K4160008). Upon activation of the GEMS receptor, STAT-induced IL-10 will be expressed and secreted via the JAK/STAT signaling pathway. In the project of TU-Eindhoven 2022, IL-10 will act as the therapeutic agent to treat ANCA-associated vasculitis.
Characterization
Characterization of IL-10 expression by the GEMS system can be found on the BBa_K4160008 page.
References